摘要
目的评价甲基磺酸索拉非尼治疗中国人转移性肾癌的疗效及安全性。方法总结我院2006年2月至10月应用甲基磺酸索拉非尼治疗的17例转移性肾癌患者的临床资料,其中2例由于在服药后8周内死亡未进行肿瘤评价。结果15例接受过1次以上实体瘤治疗反应评价标准(RECIST)评价的患者中,13例稳定,2例肿瘤进展。随访期间,3例东方肿瘤合作组体力状况评分改善,3例加重,变化幅度均为1分。不良反应一般在服药后2周左右出现,在所有接受治疗的患者中,7例发生较严重(Ⅲ～Ⅳ级)不良反应,不能耐受不良反应而减少药物剂量者3例,无1例停药,且药物不良反应在减少剂量并予一定对症支持治疗后基本可以缓解。结论甲基磺酸索拉非尼可延长转移性肾癌患者的无进展生存时间,且耐受性良好,是治疗转移性肾癌的新选择。
Objective To evaluate the outcome and safety of sorafenib in treatment of metastatic renal cancer. Methods From Feb. 2006 to Oct. 2006, 17 patients with metastatic renal cancer were treated with sorafenib; their clinical data were retrospectively analyzed. Two patients died within 8 months after sorafenib treatment and were excluded from this study. Results Fifteen patients received more than once of tumor assessment with Response Evaluation Criteria in Solid Tumours（RECIST） criteria; 13 had stable condition and 2 had progressive tumors. Three patients had improved Eastern Cooperative Oncology Group （ECOG） performance status, and another 3 patients had a deteriorated condition, with the extents of score change both being 1. The adverse reaction usually occurs at about 2 weeks after drug administration. Of all the patients in this study, 7 had severe adverse reaction（ Ⅲ-Ⅳ ）. Three patients reduced their dose of sorafenib due to adverse reaction. There was no withdrawal of drug. The adverse reaction of sorafenib could be relieved after reducing the dose of sorafenib and symptomtargeted treatment. Conclusions Sorafenib can prolong the non-progressive survival of renal cancer patients and is well tolerated; it might be a new choice for treatment of metastatic renal cell carcinoma. （Shanghai Med J, 2007, 30;828-830）
出处
《上海医学》
CAS
CSCD
北大核心
2007年第11期828-830,F0002,共4页
Shanghai Medical Journal
